Smith & Nephew plc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.35 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 29.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| SNN | VEA | |
|---|---|---|
Market Cap | $11.10B | $323.80B |
Volume | 1,051,703 | 17,001,112 |
Sector | Health | — |
52-Week High | $37.17 | $73.79 |
52-Week Low | $26.42 | $58.90 |
Typical Hold Time | 121 Days | 131 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
VEA trades at $69.86, down 0.57% with a bearish technical signal (17 sell indicators vs 4 buy). The ETF maintains strong institutional interest with multiple firms increasing positions in Q2 2026. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. The fund provides exposure to developed markets excluding US equities, with established economies like Canada and Japan.
VEA offers cost-efficient international diversification but faces near-term technical headwinds. The fund's low expense ratio and dividend yield provide structural advantages, though current bearish momentum suggests potential for further downside. Key risks include global market volatility and currency fluctuations affecting international holdings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →